



BUCKET NO.: TJU-1156

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

David Berd

QJC

Serial No.: 08/203,004

Group No.: 1813

Filed: February 28, 1994 Examiner: J. Staples

For: Composition and Method of Using Tumor Cells

QJC 1000 JAN 24 1995

I, Lori Y. Beardell, Registration No. 34,293 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

On January 12, 1995
Lori Y. Beardell
Lori Y. Beardell Reg. No. 34,293

Box Non-Fee Amendment
Commissioner of Patents & Trademarks
Washington, DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith is an amendment in the above-identified application responsive to the Restriction Requirement dated December 14, 1994.

- (xx) Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- () A verified statement claiming small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- () Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825.
- (xx) No additional fee is required.

The fee for additional claims presented in this amendment has been calculated as follows:

				SMALL ENTITY				OTHER THAN SMALL ENTITY	
	Claims Remaining After Amendment	Highest Number Previously Paid for	No. Extra	Rate	Fee	<u>OR</u>	Rate	Fee	
Total Claims	10 -	31 = (at least 20)	0	x\$11=	\$	<u>OR</u>	x\$22=	\$	
Indep. Claims	1 -	4= (at least 3)	0	x\$38=	\$	<u>OR</u>	x\$76=	\$	
First Presentation Multiple Dependent Claims				+ \$120=	\$	<u>OR</u>	\$240=	\$	
Total fee for added claims:					\$0				\$

() Please charge my Deposit Account No. 23-3050 in the amount of \$_____. This sheet is attached in triplicate.

() A check in the amount of \$____ is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

(XX) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.

(XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims.

(XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

(XX) The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.

(XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

() The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

(XX) Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.

Date: January 12, 1995



Signature

Lori Y. Beardell

Registration No. **34,293**

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100



DOCKET NO.: TJU-1156

6/2
PATENT
1/26/95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in the application of:

David Berd

Serial No.: 08/203,004

Group Art Unit: 1813

Filed: February 28, 1994

Examiner: J. Staples

For: Composition and Method of Using Tumor Cells

JAN 24 1995

I, Lori Y. Beardell, Registration No. 34,293 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

On January 12, 1995
Lori Y. Beardell
Lori Y. Beardell Reg. No. 34,293

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

RESPONSE TO RESTRICTION REQUIREMENT

This response is submitted in reply to the Examiner's restriction requirement dated December 14, 1994, the period for response expiring January 14, 1994.

In the Claims:

Please cancel claims 8 and 9, without prejudice.

Please amend the claims as follows:

Claim 1, line 3, following "a", insert --haptenized--;

Claim 1, line 7, following "extracts", delete "; said composition mixed with an immunological adjuvant";

Claim 5, lines 1-2, following "said", delete .
"composition further comprises a";

Claim 5, line 2, following "hapten", insert --is--.